胃と腸39巻2号

2004年02月発行

今月の主題 Crohn病経過例における新しい治療の位置づけ 主題

Crohn病の治療―最近の知見：文献 review

著者： 笹田寛子¹ 平田一郎¹ 勝健一¹

所属機関： ¹大阪医科大学第2内科学

ページ範囲：P.137 - P.143

要旨　Crohn病に対する治療は，日本では栄養療法が第一選択となっているが，欧米では薬物療法が主であり，今現在様々な薬物に対する臨床試験が進行中である．従来は5-ASA製剤，ステロイド，免疫抑制剤等がCrohn病の治療に主に使用されていたが，現在TNFを標的とした治療の研究が目覚しく進歩し，臨床応用されている．だが一方では，抗TNF-α抗体療法も，中和抗体の出現やコストの面等，様々な問題を残していると言える．ここでは，Crohn病に対する従来の治療薬，新しく実用化された治療薬，また現在研究段階の治療薬に分類し，主要な論文に基づいて，臨床試験成績と主な問題点について解説した．

参考文献

1）Podolsky DK. Inflammatory bowel disease. N Engl J Med 347 : 417-429, 2002

2）Rutgeerts P, Lofberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 331 : 842-845, 1994

3）Gordon RG, Brian GF, Fracois M, et al. Oral budesonide for active Crohn's disease. N Engl J Med 331 : 836-841, 1994

4）Gordon RG, Brian GF, Fracois M, et al. Oral budesonide as maintenance treatment for Crohn's disease. Gastroenterology 110 : 45-51, 1996

5）Lofberg R, Rutgeerts P, Malchow H, et al. Budesonide prolongs time to relapse in ileal and ileocecal Crohn's disease. Gut 39 : 82-86, 1996

6）Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease. Am J Gastroenterol 91 : 423-433, 1996

7）Colombel JF, Ferrari N, Debuysere H, et al. Genotype analysis of thiopurine S-methyltransferase in patient with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 118 : 1025-1030, 2000

8）Connell WR, Kamm MA, Dickson M, et al. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 343 : 1249-1252, 1994

9）Lewis JD, Schwartz JS, Lichtenstein GR. Azathioprine for maintenance of remission in Crohn's disease : benefits outweigh the risk of lymphoma. Gastroenterology 118 : 1018-1024, 2000

10）Feagan BG. Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 332 : 292-297, 1995

11）Feagan BG, Fedorak RN, Irvine EJ, et. al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 342 : 1627-1632, 2000

12）Stange EF, Modigliani R, Pena AS, et al. European trial of cyclosporine in chronic active Crohn's disease : a 12-month study. The European Study Group. Gastroenterology 109 : 774-782, 1995

13）Sandborn WJ. Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn's disease. Am J Gastroenterol 92 : 876-879, 1997

14）Lowry PW, Weaver AL, Tremaine WJ, et al. Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment-refractory Crohn's disease perianal fistulas. Inflamm Bowel Dis 5 : 239-245, 1999

15）Sandborn WJ, Present DH, Isaacs KL, et al. Tacrolimus for the treatment of fistulas in patient with Crohn's disease : a randomized, placebo-controlled trial. Gastroenterology 125 : 380-388, 2003

16）Neurath MF, Wanitschke R, Peters M, et al. Randomized trial of mycophenolate mofetil versus azathioprine for treatment of chronicactive Crohn's disease. Gut 44 : 625-628, 1999

17）Fellermann K, Steffen M, Stein J, et al. Mycophenolate lack of efficacy in chronic active inflammatory bowel disease. Aliment Pharmacol Ther 14 : 171-176, 2000

18）Prantera C, Zannoni F, Scribano ML, et al. An antibiotic regimen for the treatment of active Crohn's disease : a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol 91 : 328-332, 1996

19）Guslandi M, Mezzi G, Sorghi M, et al. Saccharomyces boulardii in maintenance treatment of Crohn's disease.Dig Dis Sci 45 : 1462-1464, 2000

20）Malchow HA. Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease? J Clin Gastroenterol 25 : 653-658, 1997

21）Gui GP, Thomas PR, Tizard ML, et al. Two-year-outcomes analysis of Crohn's disease treated with rifabutin and macrolide antibiotics. J Antimicrob Chemother 39 : 393-400, 1997

22）Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 337 : 1029-1035, 1997

23）Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 117 : 761-769, 1999

24）Hanauer SB, Feagan BG, Lichtenstein GR, et al.Maintenance infliximab for Crohn's disease : the ACCENT I randomised trial. Lancet 359 : 1541-1549, 2002

25）Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patient with Crohn's disease. N Engl J Med 340 : 1398-1405, 1999

26）Sands BE, Van DS, Bernstein C, et al. Long term treatment of fistulizing Crohn's disease. Gastroenterology 122 : A81 (abstract), 2002

27）Cohen RD, Tsang JF, Hanauer SB. Infliximab in Crohn's disease : first anniversary clinical experience. Am J Gastroenterol 95 : 3469-3477, 2000

28）Ricart E, Panaccione R, Loftus EV, et al. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic : the first 100 patients. Am J Gastroenterol 96 : 722-729, 2001

29）Sandborn WJ, Hanauer SB. Infliximab in the treatment of Crohn's disease : a user's guide for clinicians. Am J Gastroenterol 97 : 2962-2972, 2002

30）Lipsky PE, van der Heijde DM, St Clair EW, et al.Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 343 : 1594-1602, 2000

31）Farrell RJ, Alsahli M, Jeen YT, et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease : a randomized controlled trial. Gastroenterology 124 : 917-924, 2003

32）Baert F, Noman M, Vermeive S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348 : 601-608, 2003

33）Sandborn WJ, Feagan BG, Hanauer SB, et al. An engineered human antibody to TNF (CDP571) for active Crohn's disease : a randomized double-blind placebo controlled trial. Gastroenterology 120 : 1330-1338, 2001

34）Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease : a randomized, double-blind, placebo-controlled trial. Gastroenterology 121 : 1088-1094, 2001

35）Bauditz J, Haemling J, Orther M, et al. Treatment with tumor necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease. Gut 40 : 470-474, 1997

36）Bauditz J, Wedel S, Lochs H. Thalidomide reduces tumor necrosis factor alpha and interleukin 12 production in patient with chronic active Crohn's disease. Gut 50 : 196-200, 2002

37）Vasiliauskas EA, Kam LY, Abreu-Martin MT et al. An open-label pilot study of low-dose thalidomide in chronic active, steroid-dependent Crohn's disease. Gastroenterology 117 : 1278-1287, 1999

38）Ehrenpreis ED, Kane SV, Cohen LB, et al. Thalidomide therapy for patient with refractory Crohn's disease : an open label trial. Gastroenterology 117 : 1271-1277, 1999

39）Yamamoto M, Yoshizaki K, Kishimoto T, et al. IL-6 is required for the development of Th1 cell-mediated murine colitis. J Immunol 164 : 4878-4882, 2000

40）Ito H. IL-6 and Crohn's disease. Curr Drug Targets Inflamm Allergy. 2 : 125-130, 2003

41）Sander JH, Van D, Charles OE, et al. Multiple doses of intravenous Interleukin 10 in steroid refractory Crohn's disease. Gastroenterology 113 : 383-389, 1997

42）Schreiber S, Fedorak RN, Nielsen OH, et al. Safety and efficacy of recombinant human Interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology 119 : 1461-1472, 2000

43）Fedorak RN, Gangl A, Elson CO, et al. Recombinant human Interleukin 10 in the treatment of patient with mild to moderately active Crohn's disease. The Interleukin 10 Inframmatory Bowel Disease Cooperative Study Group. Gastroenterology 119 : 1473-1482, 2000

44）Sands BE, Bank S, Sninsky CA, et al. Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patient with active Crohn's disease. Gastroenterology 117 : 58-64, 1999

45）Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn's disease. N Engl J Med 348 : 24-32, 2003

46）Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, et al. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology 114 : 1133-1142, 1998

47）Shreiber S, Nikolaus S, Malchow H, et al. Antisense ICAM-1 (ISIS-2302) for subcutaneous treatment of chronic active Crohn's disease : Lack of efficacy in a prospective, double-blind, multicenter trial. Gastroenterology 121 : 268-274, 2001

48）Slonim AE, Bulone L, Damore MB, et al. A preliminary study of growth hormone therapy for Crohn's disease. N Engl J Med 342 : 1633-1637, 2000

49）Stronkhorst A, Radema S, Yong SL, et al. CD4 antibody treatment in patients with active Crohn's disease : a phase 1 dose finding study. Gut 40 : 320-327, 1997

50）Belluzzi A, Brignola C, Campieri M, et al. Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. N Engl J Med 334 : 1557-1560, 1996

51）Vaughan D, Drumm B. Treatment of fistulas with glanulocyte colony-stimulating factor in a patient with Crohn's disease. N Engl J Med 340 : 239-240, 1999

52）Sawada K, Ohnishi K, Kosaka T, et al. Leukocytapheresis therapy, performed with leukocyte removal filter, for inflammatory bowel disease. J Gastroenterol 30 : 322-329, 1995

53）Kosaka T, Sawada K, Ohnishi K, et al. Effect of leukocytapheresis therapy using a leukocyte removal filter in Crohn's disease. Intern Med 38 : 102-111, 1999

54）Lavy A, Weisz G, Adir Y, et al. Hyperbaric oxygen for perianal Crohn's disease. J Clin Gastroenterol 19 : 202-205, 1994

55）Lopez-Cubero SO, Sullivan KM, McDonald GB. Course of Crohn's disease after allogenic marrow transplantation. Gastroenterology 114 : 433-440, 1998

56）Kreisel W, Potthoff K, Bertz H, et al. Complete remission of Crohn's disease after high-dose cyclophosphamide and autologous stem cell transplantation. Bone Marrow Transplant 32 : 337-340, 2003

57）Hommes D, van den Blink B, Plasse T, et al. Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology 122 : 7-14, 2002